STAC-BBB shows widespread neuronal transduction across all cortical regions, according to Sangamo. Sangamo Therapeutics was hit hard by the loss of Pfizer as a partner at the end of last year, but ...

A $1.4 billion gene therapy alliance with Eli Lilly has come at an opportune time for Sangamo as its cash reserves start to dry up.

Congrats to Sangamo Therapeutics ... This recent licensing agreement with Eli Lilly further underscores the potential of STAC-BBB in developing genomic medicines for neurological disorders.

The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

Eli Lilly and Company traded as low as $718.81 and last traded at $718.89. Approximately 663,002 shares changed hands during trading, a decline of 80% from the average daily volume of 3,354,701 ...

Access our full analysis report here, it’s free. Branded Pharmaceuticals company Eli Lilly (NYSE:LLY) fell 6.8%. Is now the time to buy Eli Lilly? Access our full analysis report here ...

ATLANTA, April 11, 2025 /PRNewswire/ -- On April 01, 2025, OrderlyMeds received a Cease-and-Desist letter from Eli Lilly regarding the compounding of Tirzepatide. This is our open response.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eli Lilly and Co. joined several other investors in a Series A round for a Boston biotech co-founded by the Longwood Fund that's developing a drug for a rare type of blood cancer.

We recently published a list of Jim Cramer Reacts to the Surprise Market Surge and Highlights 8 Key Stocks In this article, ...